South Africa Secures Groundbreaking Twice-Yearly HIV Prevention Jab in Landmark Deal

South Africa will soon deploy a revolutionary HIV prevention injection. Health Minister Aaron Motsoaledi confirmed the rollout of lenacapavir, the world’s first twice-yearly jab. This announcement marks a pivotal moment in the nation’s long fight against the virus.

The initial supply will be limited, targeting nearly half a million people. According to Reuters, the program is funded by a $29.2 million grant from The Global Fund. An additional $5 million was allocated by a local community network.

Strategic Rollout Targets High-Risk Populations First

The first doses are scheduled for April 2026. The health ministry plans to distribute them across 23 high-incident districts. These areas span six provinces and include 360 high-performing public clinics.

Minister Motsoaledi stated this phased approach ensures the highest impact. Data shows prioritizing vulnerable groups in high-burden areas prevents the most new infections. He cautioned, however, that initial demand will likely exceed the available supply.

Funding and Licensing Hurdles Shape Long-Term Access

The minister welcomed Gilead’s reduced price of $40 per person annually. This is a significant drop from the initial $28,000 figure. Long-term success depends on integrating the drug into South Africa’s essential medicines list for self-funding.

A major controversy involves Gilead’s voluntary licensing. The company excluded South African manufacturers, granting licenses to firms in India, Egypt, and Pakistan. Gilead’s country manager stated local producers did not meet the technical standards for sterile injectables in 2024.

The introduction of lenacapavir offers a fresh option for people at risk. It is not a cure or a vaccine, but it could be a game changer. This long-acting injectable strengthens user agency and reduces barriers linked to daily pill-taking.

This new HIV prevention jab represents a monumental shift in public health strategy. South Africa’s rollout will be closely watched by the global community. Its success could redefine HIV prevention for millions worldwide.

Info at your fingertips

What is lenacapavir?

Lenacapavir is an injectable HIV prevention drug. It is administered just twice a year. The World Health Organization has recommended it as a new prevention choice.

When will the jab be available in South Africa?

The initial rollout is planned for April 2026. The first phase will target high-incident districts and clinics. Supply will be limited to around 456,000 people initially.

How much does the HIV prevention jab cost?

Gilead Sciences has set an annual price of $40 per person for this program. This is a major reduction from the original price discussed. The goal is to make it more accessible.

Why were South African manufacturers excluded from production?

Gilead stated that evaluated manufacturers did not meet technical standards for sterile injectables in 2024. The company says it remains open to future licensing if capabilities improve.

How is the rollout being funded?

The program is primarily funded by a $29.2 million grant from The Global Fund. The Networking HIV and AIDS Community of Southern Africa added another $5 million. This catalytic investment covers the first two years.